Luseogliflozin
Luseogliflozin (trade name Lusefi) is a pharmaceutical drug (an SGLT2 inhibitor) used for the treatment of type 2 diabetes mellitus.[1][2] It was approved for use in Japan in 2014.[1]
 | |
| Clinical data | |
|---|---|
| Trade names | Lusefi |
| Other names | TS-071 |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C23H30O6S |
| Molar mass | 434.55 g·mol−1 |
| 3D model (JSmol) | |
| |
References
- Markham A, Elkinson S (June 2014). "Luseogliflozin: first global approval". Drugs. 74 (8): 945–50. doi:10.1007/s40265-014-0230-8. PMID 24848756. S2CID 1770988.
- Samukawa Y, Sata M, Furihata K, Ito T, Ueda N, Ochiai H, et al. (September 2017). "Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study". Clinical Pharmacology in Drug Development. 6 (5): 439–447. doi:10.1002/cpdd.364. PMID 28783873.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.